Journal
RESPIROLOGY
Volume 26, Issue 10, Pages 982-988Publisher
WILEY
DOI: 10.1111/resp.14116
Keywords
advanced idiopathic pulmonary fibrosis; antifibrotic therapy; interstitial lung disease; mortality; nintedanib; pirfenidone; transplant-free survival
Categories
Funding
- Academy of Finland
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- Hjart-Lungfonden
- Norwegian Respiratory Society
- Nummela Sanatorium Foundation for Medical Research
- Paul and Ragna Nyberg Foundation
- Sigrid Juseliuksen Saatio
- Helsinki University Hospital
- Roche
- Karolinska University Hospital
- Karolinska Institutet
- InterMune/Roche
Ask authors/readers for more resources
The study found that patients with advanced idiopathic pulmonary fibrosis (IPF) at the initiation of antifibrotic therapy did not experience greater decline in lung function over time compared to those with mild-moderate IPF, but had significantly higher mortality rates. Prospective studies are needed to determine the effect of antifibrotic therapy in patients with advanced IPF.
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF). However, patients with advanced IPF, as defined by forced vital capacity (FVC) < 50% and/or diffusion capacity for carbon monoxide (DLCO) < 30% of predicted, have not been included in randomized trials, and the outcomes of such patients who initiate treatment are not well understood. We determined lung function, disease progression and mortality outcomes following initiation of antifibrotic therapy in patients with advanced IPF at the time of treatment initiation compared to those with mild-moderate IPF. Methods We included 502 patients enrolled in IPF registries from four Nordic countries. Linear mixed models were used to assess change in FVC and DLCO over time. Cox proportional hazards models were used to assess transplant-free survival and progression- and transplant-free survival. Results Of 502 patients, 66 (13%) had advanced IPF. Annual change in FVC was -125 ml (95% CI -163, -87) among patients with mild-moderate IPF, and +28 ml (95% CI -96, +152) among those with advanced IPF. Advanced IPF at treatment initiation was associated with poorer transplant-free survival (hazard ratio [HR] 2.39 [95% CI 1.66, 3.43]) and progression- and transplant-free survival (HR 1.60 [95% CI 1.15, 2.23]). Conclusion In a broadly representative IPF population, patients with advanced IPF at the initiation of antifibrotic therapy did not have greater lung function decline over time compared with those with mild-moderate IPF, but had substantially higher mortality. Prospective studies are needed to determine the effect of antifibrotic therapy in patients with advanced IPF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available